Esomeprazole Compared With Famotidine in the Prevention of Upper Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome or Myocardial Infarction - Esomeprazole vs. Famotidine in Prevention of GI Bleeding in ACS or MI


The use of dual antiplatelet therapy and anticoagulants is often fraught with problems of gastrointestinal bleeding (GIB) in patients presenting with acute coronary syndrome (ACS). The current trial sought to study the relative efficacy of esomeprazole, a protein pump inhibitor (PPI), versus famotidine, an H2 receptor antagonist, in ACS patients, most of whom were not at a higher risk for bleeding.